Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management

[71] Ogasawara S(2016)Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy Diabetes 65 2429-14

[72] Jim B(2010)The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice Diabetologia 53 192-553

[73] Ghanta M(2019)Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Lancet 393 1937-13

[74] Qipo A(2019)Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model Stem Cell Res Ther 10 1-546

[75] Fan Y(2018)BMSC s and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway J Cell Mol Med 22 4840-282

[76] Chuang PY(2014)Mesenchymal stem cells ameliorate diabetic glomerular fibrosis in vivo and in vitro by inhibiting TGF-β signalling via secretion of bone morphogenetic protein 7 Diab Vasc Dis Res 11 251-154

[77] Cohen HW(2019)Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines Med Sci Monit: Int Med J Exp Clin Res 25 3069-571

[78] Donate-Correa J(2015)Adipose-derived mesenchymal stem cells transplantation alleviates renal injury in streptozotocin-induced diabetic nephropathy J Histochem Cytochem 63 842-77

[79] Martín-Núñez E(2018)Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment Int J Mol Med 41 2629-14

[80] Muros-de-Fuentes M(2019)Mesenchymal stem cells prevent the progression of diabetic nephropathy by improving mitochondrial function in tubular epithelial cells Exp Mol Med 51 1-269

[71] Ogasawara S(2016)Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy Diabetes 65 2429-14

[72] Jim B(2010)The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice Diabetologia 53 192-553

[73] Ghanta M(2019)Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Lancet 393 1937-13

[74] Qipo A(2019)Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model Stem Cell Res Ther 10 1-546

[75] Fan Y(2018)BMSC s and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway J Cell Mol Med 22 4840-282

[76] Chuang PY(2014)Mesenchymal stem cells ameliorate diabetic glomerular fibrosis in vivo and in vitro by inhibiting TGF-β signalling via secretion of bone morphogenetic protein 7 Diab Vasc Dis Res 11 251-154

[77] Cohen HW(2019)Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines Med Sci Monit: Int Med J Exp Clin Res 25 3069-571

[78] Donate-Correa J(2015)Adipose-derived mesenchymal stem cells transplantation alleviates renal injury in streptozotocin-induced diabetic nephropathy J Histochem Cytochem 63 842-77

[79] Martín-Núñez E(2018)Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment Int J Mol Med 41 2629-14

[80] Muros-de-Fuentes M(2019)Mesenchymal stem cells prevent the progression of diabetic nephropathy by improving mitochondrial function in tubular epithelial cells Exp Mol Med 51 1-269